420
Participants
Start Date
September 19, 2017
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2026
Cevostamab
Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
Tocilizumab
Tocilizumab will be administered as premedication during Cycle 1.
Alfred Hospital, Melbourne
Peter MacCallum Cancer Center, East Melbourne
Memorial Sloan Kettering, New York
Mount Sinai Hospital, New York
University of Pennsylvania, Philadelphia
Clinica Universidad de Navarra, Pamplona/iruña
University of Alabama at Birmingham, Birmingham
Hospital Clinico Universitario de Salamanca, Salamanca
Tennessee Oncology - Nashville, Nashville
University of Colorado Denver, Aurora
Mayo Clinic Hospital - Arizona, Scottsdale
City of Hope, Duarte
Dana Farber Cancer Institute, Boston
The University of Texas MD Anderson Cancer Center, Houston
University of Calgary, Calgary
Princess Margaret Cancer Center, Toronto
Jewish General Hospital, Montreal
Lead Sponsor
Genentech, Inc.
INDUSTRY